Skip to main content
Digital Seminar

Psychedelic Harm Reduction and Integration in Clinical Practice


Faculty:
Elizabeth Nielson, PhD
Duration:
1 Hour
Format:
Audio and Video
Copyright:
Jul 27, 2022
Product Code:
NOS096246
Media Type:
Digital Seminar
Access:
Never expires.


Description

What do you do when a client lets you know they are going to use psychedelics on their own, as part of a ceremony, spiritual practice or because they’ve heard it can help them? Is there anything you can do to help reduce harm? And what about micro-dosing, which is gaining popularity?

Psychedelic Harm Reduction and Integration (PHRI) is a transdiagnostic and transtheoretical approach that YOU as a mental health professional can take to having conversations with people who have taken psychedelics in clinical or non-clinical settings, or who are seeking help at any stage of psychedelic use. This recording will cover the core concepts of PHRI and its applications, including discussions about microdosing, responding to requests for referrals to non-licensed providers, and working with difficult experiences. 

CPD

Planning Committee Disclosure - No relevant relationships All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners. For speaker disclosures, please see the faculty biography.


CPD

PESI Australia, in collaboration with PESI in the USA, offers quality online continuing professional development events from the leaders in the field at a standard recognized by professional associations including psychology, social work, occupational therapy, alcohol and drug professionals, counselling and psychotherapy. On completion of the training, a Professional Development Certificate is issued after the individual has answered and submitted a quiz and course evaluation. This program is worth 1 hours CPD for points calculation by your association.



Handouts

Faculty

Elizabeth Nielson, PhD's Profile

Elizabeth Nielson, PhD Related seminars and products


Dr. Elizabeth Nielson, PhD, is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a Site Co-Principal Investigator and therapist for an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and has served as a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, psilocybin-assisted treatment of treatment resistant depression, and earlier phase 2 and 3 trials of MDMA-assisted psychotherapy. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.

 

Speaker Disclosures:
Financial: Elizabeth Nielson is the co-founder of Fluence and has employment relationships with Columbia University Irving Medical Center, New York State Psychiatric Institute, and MAPS NY Private Practice Research Site. She receives a speaking honorarium from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Elizabeth Nielson is the founding member and an advisory board member of the Psychedelic Medicine Association. She is a member of the American Psychological Association and the International Society for Research on Psychedelics.


Objectives

  1. Differentiate Psychedelic Harm Reduction and Integration from Psychedelic-assisted Therapy.  
  2. Determine ways to intervene with clients who are using or micro-dosing psychedelics.
  3. Assess four theoretical pillars of the Psychedelic Harm Reduction and Integration model.  
  4. Integrate Psychedelic Harm Reduction and Integration into the larger picture of psychedelic-assisted therapies.

Outline

  • The differences between psychedelic assisted therapies & harm reduction interventions 
  • The Four foundations of psychedelic harm reduction interventions 
  • A model for integration of psychedelic applications 
  • The issue of micro-dosing among clients 
  • When clinicians are asked for referrals to non-licensed providers 
  • Working with difficult psychedelic experiences in psychotherapy 

Target Audience

  • Counsellors
  • Marriage & Family Therapists
  • Nurses
  • Nurse Practitioners
  • Physicians
  • Psychologists
  • Social Workers
  • Other Behavioral Health Professionals

Please wait ...

Back to Top